Market Overview
According to fortune business insights, the global prescription drugs market size was valued at USD 1,324.44 billion in 2025. The market is projected to grow from USD 1,415.52 billion in 2026 to USD 2,492.84 billion by 2034, exhibiting a CAGR of 7.33% during the forecast period. North America dominated the prescription drugs market with a market share of 49.66% in 2025.
Prescription drugs include a wide range of vaccines and therapies for treating chronic and acute diseases. The analysis shows that while market players are heavily engaged in clinical trials for new products, the landscape is also changing due to an increasing influx of generic equivalents. After a decline in 2020 due to the COVID-19 pandemic, the market rebounded with the resurgence of routine healthcare, a focus on COVID-19 treatments, and a high uptake of biosimilars and specialty medications.
Major Players Profiled in the Market Report:
Segments
Rising Number of Prescribed Critical Drugs to Boost "Other Prescription Drugs" Segment
Based on product type, the market is segmented into generics, orphan, and other prescription drugs. The "other prescription drugs" segment holds the largest market share (projected 71.71% in 2026). Its dominance is due to the high volume of critical and life-saving drugs prescribed for conditions like cancer, diabetes, and cardiovascular diseases, many of which are biologics without immediate generic equivalents.
Global Rise in Cancer Prevalence to Aid Dominance of the Oncology Segment
In terms of therapy, the market is segmented into oncology, central nervous system, vaccines, immunosuppressants, and others. The oncology segment is anticipated to dominate due to the increasing global prevalence of cancer, the high cost of treatment, and the rising number of regulatory approvals for targeted cancer therapies.
High Prescription Drug Spending in Hospitals to Drive Hospital Pharmacies Segment